Congress Passes Significant Federal Pharmacy Benefit Manager Reform Impacting Pharmaceutical Market Access

The Consolidated Appropriations Act, 2026 introduces sweeping pharmacy benefit manager (PBM) reforms that reshape pricing, transparency, and oversight across Medicare Part D, Medicare Advantage-Prescription Drug, and commercial markets. The legislation mandates full rebate pass-through, requires flat, fair-market-value service fees instead of price-linked compensation, and expands federal oversight of PBM arrangements. It also imposes robust new reporting and disclosure obligations, giving regulators, plan sponsors, and stakeholders greater visibility into drug pricing and PBM revenue streams. Readers will gain a clear understanding of how these changes impact pharmaceutical manufacturers, including implications for market access strategies, government price reporting, and upcoming regulatory developments.